How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,551 results for

Fluconazole

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Fluconazole

Fluconazole Top results for fluconazole - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for fluconazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

2. Low dose fluconazole and adverse pregnancy outcomes

Low dose fluconazole and adverse pregnancy outcomes DSEN Abstract: Low dose fluconazole and adverse pregnancy outcomes - CIHR Language selection Search and menus Search Search website Search Topics menu You are here: DSEN Abstract Low dose fluconazole and adverse pregnancy outcomes *This research was funded by the Drug Safety and Effectiveness Network (DSEN) and conducted by the following investigators: Anick Bérard, Odile Sheehy, Jinping Zhao, Michal Abrahamowicz, Mona Loutfy, Isabelle (...) Boucoiran, Sasha Bernatsky. The statements made herein are those of the stated authors, who are independent researchers. What is the issue? While topical azoles are the first-line treatment for fungal infections, oral fluconazole is frequently used during pregnancy. Summary and Key Messages The authors conducted a population-based cohort study to evaluate the risk of spontaneous abortions, major congenital malformations (MCM) and stillbirths in pregnant women exposed to low and high doses of fluconazole

2018 Drug Safety and Effectiveness Network

3. Yeast infection in pregnancy? Think twice about fluconazole

Yeast infection in pregnancy? Think twice about fluconazole Yeast infection in pregnancy? Think twice about fluconazole Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Yeast infection in pregnancy? Think twice about fluconazole View/ Open Date 2016-09 Format Metadata Abstract Yeast infection in pregnancy? Think twice (...) about fluconazole. This study's findings regarding the risk of miscarriage may mean it's time to forego fluconazole in favor of topical azoles as first-line treatment. Practice changer: Avoid prescribing oral fluconazole in early pregnancy because it is associated with a higher rate of spontaneous abortion than is topical azole therapy. Stength of recommendation: B: Based on a large cohort study performed in Denmark. URI Part of Citation Journal of Family Practice, 65(9) 2016: 624-626 Rights

2017 PURLS

5. Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants. Full Text available with Trip Pro

Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants. Extremely premature infants are at high risk of developing invasive candidiasis; fluconazole prophylaxis is safe and effective for reducing invasive candidiasis in this population but further study is needed. We sought to better understand the effect of prophylactic fluconazole on a selection of fluconazole-resistant Candida species.We evaluated the susceptibility to fluconazole of Candida isolates (...) from premature infants (<750 g birth weight) enrolled in a multicentre, randomized, placebo-controlled trial of fluconazole prophylaxis. Candida species were isolated through surveillance cultures at baseline (study day 0-7), period 1 (study day 8-28) and period 2 (study day 29-49). Fluconazole MICs were determined for all Candida isolates.Three hundred and sixty-one infants received fluconazole (n = 188) or placebo (n = 173). After the baseline period, Candida colonization was significantly lower

2018 Journal of Antimicrobial Chemotherapy Controlled trial quality: uncertain

6. Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species Full Text available with Trip Pro

Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species While echinocandins demonstrate excellent efficacy against Candida species in disseminated infections and demonstrate potent minimal inhibitory concentration (MIC) values under standard susceptibility testing conditions, investigation under conditions relevant to the vaginal environment was needed. We assessed the antifungal (...) activity and time-kill kinetics of the novel echinocandin rezafungin (formerly CD101) under such conditions, against Candida species relevant to vulvovaginal candidiasis (VVC).Susceptibility testing of fluconazole-susceptible and fluconazole-resistant C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. krusei was performed in RPMI at pH 7.0 and in vagina-simulative medium (VSM) at pH 4.2 for topical rezafungin, terconazole, fluconazole, and amphotericin B. Time-kill kinetics were evaluated

2018 Infectious diseases in obstetrics and gynecology

7. Fluconazole impacts the extracellular matrix of fluconazole-susceptible and -resistant Candida albicans and Candida glabrata biofilms Full Text available with Trip Pro

Fluconazole impacts the extracellular matrix of fluconazole-susceptible and -resistant Candida albicans and Candida glabrata biofilms Background: Fluconazole (FLZ) is a drug commonly used for the treatment of Candida infections. However, β-glucans in the extracellular matrices (ECMs) hinder FLZ penetration into Candida biofilms, while extracellular DNA (eDNA) contributes to the biofilm architecture and resistance. Methods: This study characterized biofilms of FLZ-sensitive (S) and -resistant (R

2018 Journal of oral microbiology

8. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies Full Text available with Trip Pro

Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies While topical azoles are the first-line treatment for fungal infections, oral fluconazole is frequently used during pregnancy. We aimed to assess the effect of exposure to low and high doses of fluconazole during pregnancy on the occurrence of spontaneous abortions, major congenital malformations and stillbirths.Within the Quebec Pregnancy Cohort (1998-2015), we identified women (...) exposed to low- (≤ 150 mg) and high-dose (> 150 mg) fluconazole, and women who were not exposed. For each case of spontaneous abortion or stillbirth, up to 5 controls were randomly selected using an incidence density sampling method matched on gestational age at diagnosis of spontaneous abortion or stillbirth (index date) and the year of the last menstrual period. For cases of major congenital malformation, we considered all liveborn babies as controls. Generalized estimation equation models were used

2019 EvidenceUpdates

9. Can oral fluconazole be used with breastfeeding?

Can oral fluconazole be used with breastfeeding? Can oral fluconazole be used with breastfeeding? – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice Menu · · Published 21st February 2017 , updated 28th November 2018 There are very limited data on the excretion of fluconazole in breast milk. Fluconazole, after a 200 mg oral dose, produces levels in breast milk similar to those found in maternal plasma. Fluconazole is recommended for use in the treatment (...) of neonates with fungal infections at a dose starting at 3 mg/kg every 72 hours. The calculated dose of fluconazole ingested by an infant feeding at times of peak milk levels of fluconazole would be approximately 0.6 mg/kg/day, which is 60% of the neonatal dose and 20% of the dose for infants aged one month and over. Fluconazole is often used to treat lactation-associated candidal infections, and has been used to treat serious candidal infections in preterm and full term neonates. There is therefore

2017 Specialist Pharmacy Services

10. Corrigendum to “Comparison between Fluconazole with Oral Protexin Combination and Fluconazole in the Treatment of Vulvovaginal Candidiasis” Full Text available with Trip Pro

Corrigendum to “Comparison between Fluconazole with Oral Protexin Combination and Fluconazole in the Treatment of Vulvovaginal Candidiasis” [This corrects the article DOI: 10.5402/2012/375806.].

2017 International scholarly research notices

11. Requirement for Ergosterol in Berberine Tolerance Underlies Synergism of Fluconazole and Berberine against Fluconazole-Resistant Candida albicans Isolates Full Text available with Trip Pro

Requirement for Ergosterol in Berberine Tolerance Underlies Synergism of Fluconazole and Berberine against Fluconazole-Resistant Candida albicans Isolates Candida albicans is one of the most common fungal pathogens. Our previous study demonstrated that concomitant use of berberine (BBR) and fluconazole (FLC) showed a synergistic action against FLC-resistant C. albicans in vitro and BBR had a major antifungal effect in the synergism, while FLC played a role of increasing the intracellular BBR

2017 Frontiers in cellular and infection microbiology

12. Ambroxol Hydrochloride Combined with Fluconazole Reverses the Resistance of Candida albicans to Fluconazole Full Text available with Trip Pro

Ambroxol Hydrochloride Combined with Fluconazole Reverses the Resistance of Candida albicans to Fluconazole In this study, we found that ambroxol hydrochloride (128 μg/mL) exhibits synergistic antifungal effects in combination with fluconazole (2 μg/mL) against resistant planktonic Candida albicans (C. albicans) cells. This combination also exhibited synergistic effects against resistant C. albicans biofilms in different stages (4, 8, and 12 h) according to the microdilution method. In vitro (...) data were further confirmed by the success of this combination in treating Galleria mellonella infected by resistant C. albicans. With respect to the synergistic mechanism, our result revealed that ambroxol hydrochloride has an effect on the drug transporters of resistant C. albicans, increasing the uptake and decreasing the efflux of rhodamine 6G, a fluorescent alternate of fluconazole. This is the first study to investigate the in vitro and in vivo antifungal effects, as well as the possible

2017 Frontiers in cellular and infection microbiology

13. Potent <i>In Vitro</i> Synergism of Fluconazole and Osthole against Fluconazole-Resistant <i>Candida albicans</i>. Full Text available with Trip Pro

Potent In Vitro Synergism of Fluconazole and Osthole against Fluconazole-Resistant Candida albicans. Osthole is a natural coumarin that exhibits wide biological and pharmacological activities such as neuroprotective, osteogenic, immunomodulation, antitumor, and anti-inflammatory effects. In this study, we investigated the antifungal effects of osthole in vitro A checkerboard microdilution assay showed that osthole has significant synergistic effect with fluconazole against (...) fluconazole-resistant Candida albicans Similar results were obtained from a growth curve assay. Meanwhile, XTT reduction assay demonstrated the synergism of fluconazole and osthole against C. albicans biofilm formation. Microarray results showed that the expression of genes involved in the oxidation-reduction process, energy metabolism, and transportation changed significantly after the combined treatment with fluconazole and osthole, and further results showed that endogenous reactive oxygen species (ROS

2017 Antimicrobial Agents and Chemotherapy

14. Fluconazole induces ROS in Cryptococcus neoformans and contributes to DNA damage in vitro. Full Text available with Trip Pro

Fluconazole induces ROS in Cryptococcus neoformans and contributes to DNA damage in vitro. Pathogenic basidiomycetous yeast, Cryptococcus neoformans, causes fatal meningitis in immunocompromised individuals. Fluconazole (FLC) is a fungistatic drug commonly administered to treat cryptococcosis. Unfortunately, FLC-resistant strains characterized by various degree of chromosomal instability were isolated from clinical patients. Importantly, the underlying mechanisms that lead to chromosomal

2018 PLoS ONE

15. Fungicidal action of geraniol against Candida albicans is potentiated by abrogated CaCdr1p drug efflux and fluconazole synergism. Full Text available with Trip Pro

Fungicidal action of geraniol against Candida albicans is potentiated by abrogated CaCdr1p drug efflux and fluconazole synergism. Among the several mechanisms of multidrug resistance (MDR), overexpression of drug efflux pumps CaCdr1p and CaMdr1p belonging to ATP binding cassette (ABC) and major facilitator superfamily (MFS) respectively remain the predominant mechanisms of candidal infections. Therefore inhibiting or modulating the function of these transporters continues to draw attention (...) . Interestingly, Ger was synergistic (FICI<0.5) with fluconazole (FLC) which is a well known antifungal drug. Furthermore, Ger sensitizes the FLC sensitive and resistant clinical matched pair of isolates Gu4/Gu5 and led to abrogated R6G efflux and depleted ergosterol. Furthermore, Rhodamine B labeling demonstrates altered mitochondrial potential with Ger which suggest possible linkage of dysfunctional mitochondria with CaCdr1p activity. We also estimated phenotypic virulence marker extracellular phospholipase

2018 PLoS ONE

16. Fluconazole Administration for the Treatment of Ductal Yeast Infections: Clinical Effectiveness and Safety

Fluconazole Administration for the Treatment of Ductal Yeast Infections: Clinical Effectiveness and Safety TITLE: Fluconazole Administration for the Treatment of Ductal Yeast Infections: Clinical Effectiveness and Safety DATE: 09 December 2013 RESEARCH QUESTIONS 1. What is the clinical evidence for the effectiveness of six-week fluconazole administration for the treatment of ductal yeast infections in breastfeeding mothers? 2. What is the short- and long-term safety of six-week fluconazole (...) administration for the treatment of ductal yeast infections in breastfeeding mothers? KEY MESSAGE No health technology assessments, systematic reviews, randomized controlled trials, or non- randomized studies were identified regarding the clinical effectiveness or safety of fluconazole for the treatment of ductal yeast infections in breastfeeding mothers. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2013, Issue 11), University of York Centre

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. Full Text available with Trip Pro

A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. Background: Cryptococcal meningitis is a leading cause of death in HIV-infected patients. International treatment guidelines recommend induction therapy with amphotericin B and flucytosine. This antifungal combination is most effective, but unfortunately flucytosine is expensive and unavailable where the burden of disease is greatest. Where unavailable, guidelines recommend (...) treatment with amphotericin and fluconazole, but this is less effective, with mortality rates of 40-50%. Faster rates of clearance of yeast from cerebrospinal fluid (CSF) are associated with better outcomes - improving the potency of antifungal therapy is likely to be an effective strategy to improve survival. Tamoxifen, a selective estrogen receptor modulator used to treat breast cancer, has anti-cryptococcal activity, appearing synergistic when combined in vitro with amphotericin, and fungicidal when

2019 Wellcome open research Controlled trial quality: uncertain

18. Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. (Abstract)

Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. To evaluate drug interactions between fluconazole and the intravenous (IV) anesthetic induction agents, ketamine and midazolam.Randomized parallel study.A group of 12 adult healthy Beagle dogs.Dogs were randomly allocated to two groups of six dogs. Dogs in group KM were administered IV ketamine (7 mg kg-1) and IV midazolam (0.25 mg kg-1), and dogs in group KMF were administered (...) fluconazole (5 mg kg-1) orally 12 and 24 hours prior to ketamine-midazolam using the same doses as KM. Sedation scores (0-4) were assigned by investigators unaware of group assignment. Heart rate (HR) and times to sternal and standing were obtained and compared between groups for differences with p < 0.05 considered statistically significant. Blood was obtained and plasma drug concentrations were measured using liquid chromatography-mass spectrometry.The times to sternal, mean 32.3 and 24.6 minutes

2019 Veterinary anaesthesia and analgesia Controlled trial quality: uncertain

19. Fluconazole Increases Osmotic Water Transport in Renal Collecting Duct through Effects on Aquaporin-2 Trafficking. (Abstract)

Fluconazole Increases Osmotic Water Transport in Renal Collecting Duct through Effects on Aquaporin-2 Trafficking. Arginine-vasopressin (AVP) binding to vasopressin V2 receptors promotes redistribution of the water channel aquaporin-2 (AQP2) from intracellular vesicles into the plasma membrane of renal collecting duct principal cells. This pathway fine-tunes renal water reabsorption and urinary concentration, and its perturbation is associated with diabetes insipidus. Previously, we identified (...) the antimycotic drug fluconazole as a potential modulator of AQP2 localization.We assessed the influence of fluconazole on AQP2 localization in vitro and in vivo as well as the drug's effects on AQP2 phosphorylation and RhoA (a small GTPase, which under resting conditions, maintains F-actin to block AQP2-bearing vesicles from reaching the plasma membrane). We also tested fluconazole's effects on water flow across epithelia of isolated mouse collecting ducts and on urine output in mice treated with tolvaptan

2019 Journal of the American Society of Nephrology

20. A Multicenter, Randomized, Open-Label Study to Compare Micafungin with Fluconazole in the Prophylaxis of Invasive Fungal Infections in Living-Donor Liver Transplant Recipients. (Abstract)

A Multicenter, Randomized, Open-Label Study to Compare Micafungin with Fluconazole in the Prophylaxis of Invasive Fungal Infections in Living-Donor Liver Transplant Recipients. Although invasive fungal infections (IFIs) contribute to substantial morbidity and mortality in liver transplant recipients, only a few randomized studies analyzed the results of antifungal prophylaxis with echinocandins. The aim of this open-label, non-inferiority study was to evaluate the efficacy and safety (...) of micafungin in the prophylaxis of IFIs in living-donor liver transplantation recipients (LDLTRs), with fluconazole as the comparator.LDLTRs (N = 172) from five centers were randomized 1:1 to receive intravenous micafungin 100 mg/day or fluconazole 100~200 mg/day (intravenous or oral). A non-inferiority of micafungin was tested against fluconazole.The per-protocol set included 144 patients without major clinical trial protocol violations: 69 from the micafungin group and 75 from the fluconazole group. Mean

2019 Journal of Gastrointestinal Surgery Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>